lh-202604080000920148false00009201482026-04-082026-04-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 8, 2026
(Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
| | | | | | | | | | | | | | |
| Delaware | | 1-11353 | | 99-2588107 |
| (State or other jurisdiction of Incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | | | | | | | | | | | | | |
| 358 South Main Street | | |
| Burlington | , | North Carolina | | 27215 |
| (Address of principal executive offices) | | (Zip Code) |
(Registrant’s telephone number including area code) 336-229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol | | Name of exchange on which registered |
| Common Stock, $0.10 par value | | LH | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
| Item 7.01 | Regulation FD Disclosure
|
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on April 9, 2026, that its Board of Directors has declared a cash dividend in the amount of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
| | | | | | | | |
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit | Exhibit Name |
| Exhibit 99.1 | |
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
| | | | | | | | |
| | |
| Date: April 9, 2026 | By: | /s/ KATHRYN W. KYLE |
| | | Kathryn W. Kyle |
| | | Executive Vice President, Chief Legal Officer and Corporate Secretary
|
FOR IMMEDIATE RELEASE
| | | | | | | | |
| Media | | Investors |
| | |
| Racquel White | | Dewey Steadman |
| Media@Labcorp.com | | Investor@Labcorp.com |
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., April 9, 2026 - Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science and accelerates innovations to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for 85% of the new drugs and therapeutic products approved in 2025 by the FDA, and performed more than 750 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
